Xenon Pharmaceuticals Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenon Pharmaceuticals Inc. (XENE) on March 9, 2022. The report details executive compensation approvals and changes to the Board of Directors effective March 9 and March 10, 2022.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2021 Non-Equity Incentive Payments:
- Simon N. Pimstone (Executive Chair): $450,389
- Ian C. Mortimer (CEO): $400,469
- Sherry Aulin (CFO): $154,773
- 2022 Base Salaries (Retroactive to Jan 1, 2022):
- Simon N. Pimstone: $525,000
- Ian C. Mortimer: $594,000
- Sherry Aulin: $425,000
Material Changes
Executive Compensation: The Compensation Committee approved 2021 incentive payments and set 2022 base salaries. 2022 salaries were benchmarked against a U.S. dollar peer group. Incentive payments for 2022 are capped at 55% of base salary for the Chair and CEO, and 40% for the CFO, contingent on corporate goals.
Board Composition: Michael Hayden notified the Board on March 9, 2022, that he will not stand for re-election. The Board appointed Simon N. Pimstone as Chair of the Board, effective upon his re-election at the Annual Meeting.
Guidance, Outlook, and Risks
Performance Goals: Executive incentives are tied to specific clinical and corporate milestones, including:
- XEN1101: End-of-Phase 2 FDA meeting and Phase 3 initiation in epilepsy; initiation of major depressive disorder proof-of-concept trial.
- XEN496: On-track completion of Phase 3 clinical trial in the first half of 2023.
- Partnerships: Achievement of milestones with Neurocrine Biosciences Inc.
- Pipeline: Transition of one discovery project to a development candidate and one clinical candidate to Phase 1.
- Financial: Execution of capital markets plan and cash-runway objectives.
Director Departure: The filing states Dr. Hayden's departure is not due to any disagreement with the Company regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the status of the XEN1101 and XEN496 clinical trials against the stated 2022/2023 milestones.
- Confirm the outcome of the Annual Meeting regarding the re-election of Dr. Pimstone as Chair and the non-re-election of Dr. Hayden.
- Review the definitive proxy statement (Schedule 14A) filed April 28, 2021, for historical context on executive compensation.
- Monitor the Company's cash runway and capital markets plan execution as a key performance indicator for executive bonuses.